Home > Resources > Whitepapers > BETTER BUILDINGS FOR BETTER PHARMACEUTICAL PRODUCTION

BETTER BUILDINGS FOR BETTER PHARMACEUTICAL PRODUCTION

May 28, 2019

Embracing and investing in new technologies is one way to get ahead, and adopting lean, efficient manufacturing procedures is another. At a fundamental level, achieving efficiency can start at the outset of a project by considering the very design of a production facility. Careful planning can cut costs and reduce waste at all stages, while at the same time ensuring the production of quality products. For both new entrants wishing to establish a position in the sector, and for established OSD producers seeking to successfully expand their product ranges, getting the end product consistently right is, of course, crucial. In this article, we take a look beyond the processes involved in drug manufacture itself, and instead turn our attention to an often overlooked and underappreciated factor of the manufacturing process: that of materials handling.

Spotlight

Reach Separations

Reach Separations specialises in chromatography for the analysis and purification of small molecules. We provide a high quality and efficient service to our clients returning samples and results quickly, allowing them to streamline their internal processes and accelerate their discovery programmes. The latest HPLC and SFC technologies are used side by side to effectively support our clients across the pharmaceutical, agrochemical and fine chemical sectors. As experts in chiral separation we have become an economical solution for a large and varied client base throughout the UK and Europe.

OTHER WHITEPAPERS

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.